<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884256</url>
  </required_header>
  <id_info>
    <org_study_id>CBT-CS103</org_study_id>
    <nct_id>NCT04884256</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-004 Ophthalmic Emulsion in Patients With Vascularized Pinguecula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cloudbreak Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cloudbreak Therapeutics, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY DESIGN:&#xD;
&#xD;
      Structure:&#xD;
&#xD;
      Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.&#xD;
&#xD;
      Duration of Treatment:&#xD;
&#xD;
      4 weeks of study treatment with 4 weeks follow-up observations.&#xD;
&#xD;
      Control:&#xD;
&#xD;
      Vehicle for CBT-004 (hereafter referred to as Vehicle).&#xD;
&#xD;
      Masking:&#xD;
&#xD;
      Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all&#xD;
      masked to the study medications.&#xD;
&#xD;
      Dosage/Dose regimen:&#xD;
&#xD;
      One drop of the assigned study medication will be administered in the study eye BID for 4&#xD;
      weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion&#xD;
      criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the&#xD;
      more severe vascularity grade at Visit 1 will be the study eye. If both eyes meet the&#xD;
      criterion and have the same severity, the left eye will be the study eye. Patients with&#xD;
      bilateral disease will administer study medication only in the study eye. The fellow eyes in&#xD;
      all study subjects will be untreated.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Patients will be randomized in equal ratio to receive vehicle, 0.01%, and 0.024% CBT-004. The&#xD;
      randomization will be stratified by pinguecula vascularity grade (3 or 4) derived from Visit&#xD;
      1 photo.&#xD;
&#xD;
      Visit schedule:&#xD;
&#xD;
      The study will consist of 5 scheduled visits:&#xD;
&#xD;
        -  Screening visit (Day-7) (Visit 1)&#xD;
&#xD;
        -  Day 1: baseline and randomization visit (Visit 2)&#xD;
&#xD;
        -  Weeks 2: Visits 3&#xD;
&#xD;
        -  Week 4: Visit 4&#xD;
&#xD;
        -  Week 8: final follow-up and exit visit (Visit 5)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Visual acuity, biomicroscopy, intraocular pressure, ophthalmoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pinguecula Vascularity</measure>
    <time_frame>1 month</time_frame>
    <description>Change of the pinguecula vascularity grade (0-4) from baseline (Day 1) at Week 4; Score 0 is the least severe while score 4 is the most severe</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pinguecula</condition>
  <arm_group>
    <arm_group_label>CBT-004</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.01% CBT-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.024% CBT-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBT-004</intervention_name>
    <description>Dose response study</description>
    <arm_group_label>0.01% CBT-004</arm_group_label>
    <arm_group_label>0.024% CBT-004</arm_group_label>
    <arm_group_label>CBT-004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pinguecula with a vascularity grade ≥ 3 on a 5-point (0-4) scale.&#xD;
&#xD;
          -  Ocular bothersome questionnaire score ≥ 2 on a 5-point (0-4) scale.&#xD;
&#xD;
          -  ≥ 18 years of age.&#xD;
&#xD;
          -  Able to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled systemic disease, in the opinion of the investigator.&#xD;
&#xD;
          -  Active ocular disease other than pinguecula that may confound the study data,&#xD;
             including but not limited to severe dry eye disease, pterygium, uncontrolled&#xD;
             blepharitis, anterior membrane dystrophy, Salzmann's, glaucoma, or active ocular&#xD;
             infection.&#xD;
&#xD;
          -  History of ocular herpes disease, iritis/uveitis, in either eye.&#xD;
&#xD;
          -  Any ocular surgical procedure within the last 3 months or anticipated ocular surgery&#xD;
             during the study, in either eye.&#xD;
&#xD;
          -  Anticipated wearing of contact lenses during any portion of the study. Patients, who&#xD;
             wear soft contact lenses should discontinue wearing them at least 7 days prior to Day&#xD;
             1 visit. Patients wearing rigid gas permeable or hard contact lenses should&#xD;
             discontinue wearing them at least 3 weeks prior to Day 1 visit.&#xD;
&#xD;
          -  Female patients who are pregnant, nursing, or planning a pregnancy during the study.&#xD;
&#xD;
          -  Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days prior to entry into this study.&#xD;
&#xD;
          -  History of myocardial infarction or stroke.&#xD;
&#xD;
          -  Any condition or situation which, in the investigator's opinion, may put the patient&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with the patient's participation in the study.&#xD;
&#xD;
          -  Known allergy or sensitivity to the study medication(s) or its components.&#xD;
&#xD;
          -  Current or anticipated use of topical ophthalmic medications in the study eye.&#xD;
             Patients must have discontinued use of ophthalmic medications in the study eye for at&#xD;
             least 2 weeks (4 weeks for Restasis® or Xiidra®) prior to Day 1 visit. Artificial&#xD;
             tears are allowed in the study eye until 7 days prior to Visit 1 and should not be&#xD;
             used during the treatment phase of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bing Leng, MD</last_name>
    <phone>19493952891</phone>
    <email>leng_bing@cloudbreaktherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Van Dinh, MBA</last_name>
    <phone>19493945308</phone>
    <email>dinh_van@cloudbreaktherapeutics.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pinguecula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

